Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Plerixafor. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 known ✓ | P61073 | 16/20 | 0.93 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.93 |
| ▸ | MEN1 | O00255 | 1/20 | 0.93 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.93 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.93 |
| ▸ | CCR2 | P41597 | 1/20 | 0.93 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.93 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.93 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490414 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL19038 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL5611617 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL1259171 | 0.95 | CXCR4 (0.90) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7610931 | 0.95 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL414153 | 0.95 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL6889125 | 0.95 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7612104 | 0.95 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL123040 | 0.93 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL14065686 | 0.93 | CXCR4 (0.93) | CXCR4HRH3MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605410-B2 | Mitochondria-enriched genetically engineered cells and uses thereof | MINOVIA THERAPEUTICS LTD. (IL) | 2026-04-21 | — | — | US | disclosed |
| US-12502408-B2 | Mitochondrial augmentation therapy for primary mitochondrial diseases | MINOVIA THERAPEUTICS LTD. (IL) | 2025-12-23 | — | — | US | disclosed |
| WO-2025045894-A1 | METHODS AND KITS FOR DIAGNOSING CAUSE OF NEPHROTIC SYNDROME AND GUIDING THERAPY | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-03-06 | — | — | WO | disclosed |
| US-20240415894-A1 | MITOCHONDRIAL AUGMENTATION THERAPY WITH STEM CELLS ENRICHED WITH FUNCTIONAL MITOCHONDRIA | MINOVIA THERAPEUTICS LTD. (IL) | 2024-12-19 | — | — | US | disclosed |
| CN-117017948-A | Application of DPPA-entrapped AMD3100 nanoparticle in immunotherapy of residual cancer after liver cancer IRFA | 中山大学孙逸仙纪念医院 | 2023-11-10 | — | — | CN | disclosed |
| US-20230338427-A1 | MITOCHONDRIAL AUGMENTATION THERAPY | MINOVIA THERAPEUTICS LTD. (IL) | 2023-10-26 | — | — | US | disclosed |
| CN-116726199-A | Transient temperature-based delivery of ZSSCAN 4 nucleic acids and proteins to cells and tissues | 伊利克斯根治疗公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230190769-A1 | E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-22 | — | — | US | disclosed |
| US-20230133409-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2023-05-04 | — | — | US | disclosed |
| US-20230123731-A1 | MITOCHONDRIA-ENRICHED GENETICALLY ENGINEERED CELLS AND USES THEREOF | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2023-04-20 | — | — | US | disclosed |
| WO-2015028831-A1 | CXCL12 (CHEMOKINE (C-X-C MOTIF) LIGAND 12) AND IGFBP2 INHIBITORS FOR THE APPLICATION IN THE TREATMENT OF DIABETES MELLITUS ASSOCIATED PANCREATIC CANCER | FIRNEISZ GÁBOR (HU) | 2015-03-05 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | ANGIOTECH INTERNATIONAL AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| WO-2009037093-A1 | COSMETIC PREPARATION AND METHOD TO OBTAIN A SOMATIC STEM CELL PREPARATION | SCHIEFELBEIN JUERGEN PROF DR M (ES) | 2009-03-26 | — | — | WO | disclosed |
| EP-1978930-A2 | SUTURES AND ANTI-SCARRING AGENTS | Angiotech Pharmaceuticals, Inc. (CA) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605410-B2 | Mitochondria-enriched genetically engineered cells and uses thereof | TFAM, CS, MT-CO1 | CXCR4 807/4885HRH3 4757/4885MEN1 4125/4885 |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | CXCR4 1185/4885HRH3 685/4885MEN1 2464/4885 |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | GAP43, TNNC1, GJB2 | CXCR4 1284/4885HRH3 1439/4885MEN1 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.